Defining the genetics of thrombotic microangiopathies

Transfusion and Apheresis Science

Volumn 54, Issue 2, 2016, Pages 212-219

  Vieira Martins, Paula ^a   El Sissy, Carine ^a   Bordereau, Pauline ^a   Gruber, Aurelia ^a   Rosain, Jeremie ^a   Fremeaux Bacchi, Veronique ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Complement; Thrombotic microangiopathy; Variant

Indexed keywords

CD46 PROTEIN, HUMAN; COMPLEMENT; MEMBRANE COFACTOR PROTEIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANIMAL; GENETIC POLYMORPHISM; GENETICS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN GENOME; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAMTS13 PROTEIN; ANIMALS; ANTIGENS, CD46; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT SYSTEM PROTEINS; GENOME, HUMAN; HUMANS; POLYMORPHISM, GENETIC; THROMBOTIC MICROANGIOPATHIES;

EID: 84970023099     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2016.04.011     Document Type: Review

References (61)

1. George JN, Nester CM Syndromes of thrombotic microangiopathy. N Engl J Med 2014, 371:654-666.
2. Noris M, Mescia F, Remuzzi G STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012, 8:622-633.
3. Spinale JM, Ruebner RL, Kaplan BS, Copelovitch L Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr 2013, 25:203-208.
4. Loupiac A, Elayan A, Cailliez M, Adra AL, Decramer S, Thouret MC, et al. Diagnosis of Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Infect Dis J 2013, 32:1045-1049.
5. Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016, 31:15-39.
6. Noris M, Remuzzi G Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:1676-1687.
7. Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, et al. Atypical aHUS: state of the art. Mol Immunol 2015, 67:31-42.
8. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013, 8:554-562.
9. Perez-Rodriguez A, Loures E, Rodriguez-Trillo A, Costa-Pinto J, Garcia-Rivero A, Batlle-Lopez A, et al. Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): a short review. Thromb Res 2014, 134:1171-1175.
10. Froese DS, Kopec J, Fitzpatrick F, Schuller M, McCorvie TJ, Chalk R, et al. Structural Insights into the MMACHC-MMADHC protein complex involved in vitamin B12 trafficking. J Biol Chem 2015, 290:29167-29177.
11. Richard E, Jorge-Finnigan A, Garcia-Villoria J, Merinero B, Desviat LR, Gort L, et al. Genetic and cellular studies of oxidative stress in methylmalonic aciduria (MMA) cobalamin deficiency type C (cblC) with homocystinuria (MMACHC). Hum Mutat 2009, 30:1558-1566.
12. Fischer S, Huemer M, Baumgartner M, Deodato F, Ballhausen D, Boneh A, et al. Clinical presentation and outcome in a series of 88 patients with the cblC defect. J Inherit Metab Dis 2014, 37:831-840.
13. Liu MY, Yang YL, Chang YC, Chiang SH, Lin SP, Han LS, et al. Mutation spectrum of MMACHC in Chinese patients with combined methylmalonic aciduria and homocystinuria. J Hum Genet 2010, 55:621-626.
14. Grange S, Bekri S, Artaud-Macari E, Francois A, Girault C, Poitou AL, et al. Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet 2015, 386:1011-1012.
15. Cornec-Le Gall E, Delmas Y, De Parscau L, Doucet L, Ogier H, Benoist JF, et al. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis 2014, 63:119-123.
16. Komhoff M, Roofthooft MT, Westra D, Teertstra TK, Losito A, van de Kar NC, et al. Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency. Pediatrics 2013, 132. e540-4.
17. Lerner-Ellis JP, Anastasio N, Liu J, Coelho D, Suormala T, Stucki M, et al. Spectrum of mutations in MMACHC, allelic expression, and evidence for genotype-phenotype correlations. Hum Mutat 2009, 30:1072-1081.
18. Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013, 45:531-536.
19. Bruneau S, Neel M, Roumenina LT, Frimat M, Laurent L, Fremeaux-Bacchi V, et al. Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation. Blood 2015, 125:1038-1046.
20. Westland R, Bodria M, Carrea A, Lata S, Scolari F, Fremeaux-Bacchi V, et al. Phenotypic expansion of DGKE-associated diseases. J Am Soc Nephrol 2014, 25:1408-1414.
21. Mele C, Lemaire M, Iatropoulos P, Piras R, Bresin E, Bettoni S, et al. Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2015, 10:1011-1019.
22. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT Complement system part I - molecular mechanisms of activation and regulation. Front Immunol 2015, 6:262.
23. Cameron JS, Vick R Letter: plasma-C3 in haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura. Lancet 1973, 2:975.
24. Michaux K, Bacchetta J, Javouhey E, Cochat P, Fremaux-Bacchi V, Sellier-Leclerc AL Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency. Pediatr Nephrol 2014, 29:2415-2419.
25. Cho HY, Lee BS, Moon KC, Ha IS, Cheong HI, Choi Y Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol 2007, 22:874-880.
26. Wilson V, Darlay R, Wong W, Wood KM, McFarlane J, Schejbel L, et al. Genotype/phenotype correlations in complement factor H deficiency arising from uniparental isodisomy. Am J Kidney Dis 2013, 62:978-983.
27. Servais A, Noel LH, Dragon-Durey MA, Gubler MC, Remy P, Buob D, et al. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum Pathol 2011, 42:1305-1311.
28. Couzi L, Contin-Bordes C, Marliot F, Sarrat A, Grimal P, Moreau JF, et al. Inherited deficiency of membrane cofactor protein expression and varying manifestations of recurrent atypical hemolytic uremic syndrome in a sibling pair. Am J Kidney Dis 2008, 52:e5-9.
29. Bhatia D, Khandelwal P, Sinha A, Hari P, Cheong HI, Bagga A Incomplete penetrance of CD46 mutation causing familial atypical hemolytic uremic syndrome. Pediatr Nephrol 2015, 30:2215-2220.
30. Bu F, Borsa N, Gianluigi A, Smith RJ Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol 2012, 2012:370426.
31. Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ New functional and structural insights from updated mutational databases for complement factor H, factor I, membrane cofactor protein and C3. Biosci Rep 2014, 34.
32. Blaum BS, Hannan JP, Herbert AP, Kavanagh D, Uhrin D, Stehle T Structural basis for sialic acid-mediated self-recognition by complement factor H. Nat Chem Biol 2015, 11:77-82.
33. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004, 15:787-795.
34. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010, 5:1844-1859.
35. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010, 31. E1445-60.
36. Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013, 24:475-486.
37. Sansbury FH, Cordell HJ, Bingham C, Bromilow G, Nicholls A, Powell R, et al. Factors determining penetrance in familial atypical haemolytic uraemic syndrome. J Med Genet 2014, 51:756-764.
38. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 2011, 365:8-26.
39. Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998, 53:836-844.
40. Abarrategui-Garrido C, Martinez-Barricarte R, Lopez-Trascasa M, de Cordoba SR, Sanchez-Corral P Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009, 114:4261-4271.
41. Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, et al. Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. Kidney Int 2010, 77(4):339-349.
42. Kavanagh D, Yu Y, Schramm EC, Triebwasser M, Wagner EK, Raychaudhuri S, et al. Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum Mol Genet 2015, 24:3861-3870.
43. van de Ven JP, Nilsson SC, Tan PL, Buitendijk GH, Ristau T, Mohlin FC, et al. A functional variant in the CFI gene confers a high risk of age-related macular degeneration. Nat Genet 2013, 45:813-817.
44. Liszewski MK, Atkinson JP Complement regulator CD46: genetic variants and disease associations. Hum Genomics 2015, 9:7.
45. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007, 104:240-245.
46. Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, et al. Complement factor B mutations in atypical hemolytic uremic syndrome - disease-relevant or benign?. J Am Soc Nephrol 2014, 25:2053-2065.
47. Schramm EC, Roumenina LT, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, et al. Functional mapping of the interactions between complement C3 and regulatory proteins using atypical hemolytic uremic syndrome-associated mutations. Blood 2015, 125.
48. Seddon JM, Yu Y, Miller EC, Reynolds R, Tan PL, Gowrisankar S, et al. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet 2013, 45:1366-1370.
49. Valoti E, Alberti M, Tortajada A, Garcia-Fernandez J, Gastoldi S, Besso L, et al. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. J Am Soc Nephrol 2015, 26:209-219.
50. Sullivan M, Rybicki LA, Winter A, Hoffmann MM, Reiermann S, Linke H, et al. Age-related penetrance of hereditary atypical hemolytic uremic syndrome. Ann Hum Genet 2011, 75:639-647.
51. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Berges LC, Lopez-Trascasa M, Sanchez-Corral P, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005, 14:703-712.
52. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:345-357.
53. Bu F, Borsa NG, Jones MB, Takanami E, Nishimura C, Hauer JJ, et al. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol 2016, 27:1245-1253.
54. Blanc C, Roumenina LT, Ashraf Y, Hyvarinen S, Sethi SK, Ranchin B, et al. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol 2012, 189:3528-3537.
55. Dragon-Durey MA, Blanc C, Marliot F, Loirat C, Blouin J, Sautes-Fridman C, et al. The high frequency of complement factor H-related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009, 46:447-450.
56. Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 2014, 85:1151-1160.
57. Bhattacharjee A, Reuter S, Trojnar E, Kolodziejczyk R, Seeberger H, Hyvarinen S, et al. The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease. J Biol Chem 2015, 290:9500-9510.
58. Sorvillo N, van Haren SD, Kaijen PH, ten Brinke A, Fijnheer R, Meijer AB, et al. Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells. Blood 2013, 121:3502-3510.
59. Kavanagh D, Burgess R, Spitzer D, Richards A, Diaz-Torres ML, Goodship JA, et al. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation. Mol Immunol 2007, 44:3162-3167.
60. Nilsson SC, Karpman D, Vaziri-Sani F, Kristoffersson AC, Salomon R, Provot F, et al. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol 2007, 44:1835-1844.
61. Tortajada A, Pinto S, Martinez-Ara J, Lopez-Trascasa M, Sanchez-Corral P, de Cordoba SR Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance. Kidney Int 2012, 81:56-63.